-

09:00:10 PM

LIVE Real Time GSK Stock Market News

GSK - Glaxosmithkline plc

05/03/21 9:37 AM

NYSE : GSK

Voltaren Arthritis Pain Gel Empowers Early Morning Risers Living with Osteoarthritis

GSK Consumer Healthcare (LSE/NYSE: GSK), the makers of Voltaren Arthritis Pain Gel (diclofenac sodium topical gel, 1%) today revealed new data that uncovers a painful truth: for people with osteoarthritis (OA), mornings can be the most difficult part of the

RHEA-AI

neutral

04/22/21 4:33 PM

NYSE : GSK

FDA grants accelerated approval for GSK's JEMPERLI (dostarlimab-gxly) for women with recurrent or advanced dMMR endometrial cancer

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved JEMPERLI (dostarlimab-gxly), a programmed death receptor-1 (PD-1) blocking antibody, based on the company's Biologics License Application. JEMPERLI

RHEA-AI

positive

04/19/21 9:08 AM

NYSE : GSK

Advil to Reduce Plastic in Over 80 Million Bottles by 20% with New Sustainable Plastic Technology

GSK Consumer Healthcare (LSE/NYSE: GSK), the maker of Advil , today announced its commitment to reducing the plastic in over 80 million Advil bottles 1 by 20%, which will result in a reduction of nearly 500,000 pounds of plastic in the environment. By

RHEA-AI

neutral

04/15/21 9:00 AM

NYSE : GSK

GSK Global Head of Vaccine Research and Development Joins Viome To Tackle Chronic Diseases

Viome , a mission-driven systems biology company aiming to help individuals improve their health, today announced the appointment of Dr. Emmanuel Hanon as Global Head of Research and Development (R&D). Dr. Hanon is a healthcare veteran hailing from

RHEA-AI

neutral

04/01/21 11:11 AM

NYSE : GSK

Flonase teams up with Major League Baseball and World Series champion Cody Bellinger to change the game on allergy season

GSK Consumer Healthcare (LSE/NYSE: GSK) announced today that Flonase Allergy Relief (Flonase) is partnering with World Series champion and seasonal allergy-sufferer Cody Bellinger of the Los Angeles Dodgers as the new face of the brand's "Change The Game"

RHEA-AI

neutral

04/01/21 9:15 AM

NYSE : GSK

Flonase teams up with Major League Baseball and World Series champion Cody Bellinger to change the game on allergy season

GSK Consumer Healthcare (LSE/NYSE: GSK) announced today that Flonase Allergy Relief (Flonase) is partnering with World Series champion and seasonal allergy-sufferer Cody Bellinger of the Los Angeles Dodgers as the new face of the brand's "Change The Game"

RHEA-AI

neutral

03/29/21 8:30 AM

NYSE, Nasdaq : LLY, GSK, VIR

Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19

Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced topline data from the expanded Phase 2 BLAZE-4 trial studying low-risk adult patients with mild

RHEA-AI

negative

02/16/21 10:01 AM

NYSE : GSK

TUMS Expands Portfolio to Meet Consumer Demands for Naturally-Sourced Products

GSK Consumer Healthcare (LSE/NYSE: GSK) today announced the launch of TUMS Naturals, a new naturally-powered antacid joining the TUMS portfolio. As America's #1 heartburn relief medicine, TUMS is building its already expansive portfolio to meet growing

RHEA-AI

neutral

02/01/21 10:00 AM

NYSE : GSK

TUMS(R) Kicks Off $55,000 #TUMSBingoSweepstakes for the BIG GAME

GlaxoSmithKline (LSE: GSK) (NYSE: GSK) - This year, the #TUMSBingoSweepstakes is the BIG GAME within the BIG GAME and takes place on a day known for indulging in heartburn-inducing food and fans experiencing TUMSworthy moments. TUMS(R), America's #1

RHEA-AI

positive

01/27/21 6:45 AM

NYSE, Nasdaq : LLY, GSK, VIR

Lilly, Vir Biotechnology and GSK announce first patient dosed in expanded BLAZE-4 trial evaluating bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19

Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced a collaboration to evaluate a combination of two COVID-19 therapies in low-risk patients with

RHEA-AI

neutral